Related Experiment Videos
Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide
G A Higgins1, P Nguyen, E M Sellers
1Clinical Psychopharmacology Program, Addiction Research Foundation, Toronto, Ontario, Canada.
European Journal of Pharmacology
|May 17, 1991
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Psilocybin: Good Trip or Bad Trip.
Clinical pharmacology and therapeutics·2017
Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.
The Journal of pharmacology and experimental therapeutics·2016
Deconstructing Designer Drugs.
Clinical pharmacology and therapeutics·2016
The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Clinical pharmacology and therapeutics·2016
Update on tamper-resistant drug formulations.
Drug and alcohol dependence·2013
Cognitive toxicity of drugs used in the elderly.
Dialogues in clinical neuroscience·2011
Class-specific and cumulative effects of psychotropic medication on sleep architecture: a polysomnographic retrospective study.
European journal of pharmacology·2026
Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.
European journal of pharmacology·2026
Overview of exosomal non-coding RNAs in cardiovascular disease using high throughput sequencing.
European journal of pharmacology·2026
MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential.
European journal of pharmacology·2026
Topical treatment of rosacea: update and outlook.
International journal of pharmaceutics·2026
Structural and molecular insights into the binding mechanisms of β-glucosidase-ascorbic acid-rutin/isoquercetin ternary systems.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026